Sirolimus is under clinical development by OrphAI Therapeutics and currently in Phase II for Bronchiolitis Obliterans.
Addressing Point-of-Care Ultrasound’s Shadow IT Problem
Point-of-care ultrasound (POCUS) is taking hold across healthcare, and for good reason. By administering ultrasound technology at the point of care, whether that be the